Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report sent to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of NASDAQ:AKTX opened at $1.17 on Tuesday. Akari Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.50. The business has a fifty day moving average of $1.89 and a 200-day moving average of $2.69.

Institutional Trading of Akari Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKTX. Renaissance Technologies LLC lifted its holdings in shares of Akari Therapeutics by 411.4% during the 1st quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 228,100 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Akari Therapeutics during the 2nd quarter valued at about $55,000. LPL Financial LLC bought a new position in shares of Akari Therapeutics during the 2nd quarter valued at about $83,000. Omnia Family Wealth LLC lifted its holdings in shares of Akari Therapeutics by 48.2% during the 4th quarter. Omnia Family Wealth LLC now owns 87,628 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 28,511 shares in the last quarter. Finally, Sabby Management LLC lifted its holdings in shares of Akari Therapeutics by 116.5% during the 1st quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock valued at $1,443,000 after purchasing an additional 4,273,528 shares in the last quarter. 5.06% of the stock is currently owned by institutional investors and hedge funds.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.